Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two prominent investor conferences in March 2026. The company’s CEO, Seth Lederman, M.D., will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, in Boston. Additionally, Tonix will engage in one-on-one meetings at the Barclays 28th Annual Healthcare Conference from March 10-12, 2026, in Miami Beach. These appearances come on the heels of the FDA approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years.
The presentations are expected to focus on Tonix’s commercial-stage CNS portfolio and its immunology pipeline. TONMYA, the company’s flagship product, targets fibromyalgia, a chronic pain condition affecting millions. Tonix also markets Zembrace SymTouch and Tosymra for acute migraine. Beyond commercial products, Tonix is advancing TONMYA into Phase 2 trials for major depressive disorder and acute stress disorder. The pipeline includes TNX-2900 for Prader-Willi syndrome, a rare genetic disorder, and immunology candidates such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a CD40 ligand inhibitor for kidney transplant rejection.
The investor conferences provide a platform for Tonix to highlight its strategic focus on CNS and immunology, areas with significant unmet medical needs. Participation in these events underscores Tonix’s commitment to engaging with the investment community and advancing its pipeline. For more details, the full press release is available at https://ibn.fm/TToz2. Updates on TNXP can be found at https://ibn.fm/TNXP.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company’s CNS commercial infrastructure supports its marketed products, and it is maximizing the science behind TONMYA in Phase 2 clinical trials. With a robust pipeline, Tonix aims to address high unmet medical needs in both CNS and immunology. The upcoming conferences offer an opportunity for investors to gain insights into the company’s strategy and progress.
